FDA Approves First Radioligand Therapy for Hormone-Sensitive Metastatic Prostate Cancer in Major Oncology Shift

The U.S. Food and Drug Administration has approved a major expansion for a targeted radiation drug, fundamentally shifting how oncologists treat advanced prostate cancer. On July 31, 2026, regulators cleared Novartis's Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for patients with metastatic hormone-sensitive prostate cancer (mHSPC).[1][2]

Previously, this radioligand therapy was reserved as a last line of defense for patients whose cancer had stopped responding to hormone-blocking drugs. Now, it can be deployed much earlier in the disease's progression, nearly doubling the number of eligible patients who can receive the treatment.[2][8]

The decision marks a significant milestone in the field of radioligand therapy, a precision medicine approach that delivers radiation directly to cancer cells while largely sparing surrounding healthy tissue.[5][6]

To understand the significance of the approval, it is necessary to look at how prostate cancer typically progresses. When the disease spreads beyond the prostate, becoming metastatic, the first-line treatment is usually androgen deprivation therapy—starving the cancer of the testosterone it needs to grow.[4]

At this stage, the cancer is considered "hormone-sensitive" or "androgen pathway modulation-naive/sensitive." However, despite standard treatments, about half of these men will see their cancer mutate and progress within 20 months, becoming "castration-resistant."[2][7]

Pluvicto aims to intercept the disease before that resistance fully takes hold. The drug works as a microscopic homing missile. It consists of a targeting compound, known as a ligand, bound to a radioactive isotope called Lutetium-177.[5]

The ligand specifically seeks out and binds to prostate-specific membrane antigen (PSMA), a transmembrane protein heavily overexpressed on the surface of most prostate cancer cells. Once attached, the Lutetium-177 emits beta radiation, damaging the cancer cell's DNA and triggering cell death.[8]

Because the beta radiation only travels a very short distance—a fraction of a millimeter—it concentrates the destructive energy precisely where it is needed, minimizing damage to the rest of the body.[5]

The FDA's expanded approval was anchored by data from the Phase III PSMAddition trial, a massive study involving 1,144 patients globally.[1][6]

Participants were randomly assigned to receive either standard hormone therapy—an androgen receptor pathway inhibitor (ARPI)—alone, or standard therapy combined with six infusions of Pluvicto spaced six weeks apart.[4][6]

The results demonstrated a clear clinical benefit. In the primary analysis, the Pluvicto combination reduced the risk of radiographic progression or death by 28% compared to standard care alone.[2][3]

Subsequent updated data presented by Novartis showed that benefit widening to a 33% reduction in the risk of progression or death, with a positive trend toward overall survival, though those long-term data remain immature.[2][7]

"The treatment landscape for mHSPC is evolving, and this approval reflects a growing recognition that earlier treatment intensification matters," noted Dr. Michael Morris, a principal investigator for the trial at Memorial Sloan Kettering Cancer Center.[2][3]

However, the integration of radioligand therapy into earlier lines of care is not without complexities and uncertainties. First, patient selection requires specialized diagnostics.[7]

Before receiving Pluvicto, patients must undergo a specialized PSMA PET scan, using an imaging agent like Locametz, to confirm their tumors actually express enough of the PSMA protein to make the drug effective.[4][5]

Second, the treatment carries distinct toxicities. In the PSMAddition trial, severe adverse events—classified as grade 3 or higher—occurred in 50.7% of patients receiving Pluvicto, compared to 43% in the control group.[3][7]

The radioactive nature of the drug means it can suppress bone marrow function, leading to anemia and a drop in white blood cells. It also carries risks of renal toxicity and requires patients to follow specific radiation safety protocols at home to protect their families.[4][6]

Furthermore, some clinical skeptics and key opinion leaders have expressed caution about broad, immediate adoption. While the drug clearly delays the time until the cancer grows on a scan, the data on whether it actually extends overall survival remains immature, raising questions about the high incremental cost of early intervention.[7]

There are also logistical hurdles. Radioligand therapies have complex, just-in-time supply chains because the radioactive isotopes decay rapidly. Novartis has invested heavily in this infrastructure, opening five manufacturing sites in the U.S. to meet the anticipated surge in demand.[2][7]

Despite these challenges, the approval represents a paradigm shift. By moving targeted radiation to the hormone-sensitive setting, oncologists now have a powerful new tool to aggressively manage metastatic prostate cancer from the moment it is diagnosed, rather than waiting for standard therapies to fail.[5][8]